Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 3884
118th Congress(2023-2024)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Active
Active
Passed House on Sep 23, 2024
Overview
Text
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 3884 (Introduced-in-House)


118th CONGRESS
1st Session
H. R. 3884


To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

IN THE HOUSE OF REPRESENTATIVES

June 7, 2023

Mr. Burgess (for himself, Mr. Davis of Illinois, and Mr. Carter of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023”.

SEC. 2. Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.

Section 1106(b)(6) of the Public Health Service Act (42 U.S.C. 300b–5(b)(6)) is amended by striking “2019 through 2023” and inserting “2024 through 2028”.